S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NYSE:MYOV

Myovant Sciences (MYOV) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$26.98
▼
$27.00
50-Day Range
$26.88
▼
$26.99
52-Week Range
$7.67
▼
$27.06
Volume
2.26 million shs
Average Volume
1.17 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

MYOV vs. MORF, INSM, RVNC, GLPG, SDGR, XENE, CORT, NUVL, BHC, and SAGE

Should you be buying Myovant Sciences stock or one of its competitors? The main competitors of Myovant Sciences include Morphic (MORF), Insmed (INSM), Revance Therapeutics (RVNC), Galapagos (GLPG), Schrödinger (SDGR), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Nuvalent (NUVL), Bausch Health Companies (BHC), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical preparations" industry.

Myovant Sciences vs.

Morphic (NASDAQ:MORF) and Myovant Sciences (NYSE:MYOV) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

79.8% of Morphic shares are owned by institutional investors. Comparatively, 30.6% of Myovant Sciences shares are owned by institutional investors. 28.1% of Morphic shares are owned by insiders. Comparatively, 1.9% of Myovant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Morphic currently has a consensus price target of $70.33, suggesting a potential upside of 14.23%. Myovant Sciences has a consensus price target of $21.33, suggesting a potential downside of 20.93%. Given Morphic's stronger consensus rating and higher possible upside, equities analysts clearly believe Morphic is more favorable than Myovant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Morphic
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Myovant Sciences
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Myovant Sciences received 140 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 61.78% of users gave Myovant Sciences an outperform vote while only 60.98% of users gave Morphic an outperform vote.

CompanyUnderperformOutperform
MorphicOutperform Votes
75
60.98%
Underperform Votes
48
39.02%
Myovant SciencesOutperform Votes
215
61.78%
Underperform Votes
133
38.22%

Morphic has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.

Myovant Sciences has a net margin of -48.47% compared to Morphic's net margin of -92.38%. Myovant Sciences' return on equity of 0.00% beat Morphic's return on equity.

Company Net Margins Return on Equity Return on Assets
Morphic -92.38% -16.67% -15.79%
Myovant Sciences -48.47% N/A -39.36%

In the previous week, Morphic had 8 more articles in the media than Myovant Sciences. MarketBeat recorded 8 mentions for Morphic and 0 mentions for Myovant Sciences. Morphic's average media sentiment score of 0.26 beat Myovant Sciences' score of 0.00 indicating that Morphic is being referred to more favorably in the media.

Company Overall Sentiment
Morphic Neutral
Myovant Sciences Neutral

Morphic has higher earnings, but lower revenue than Myovant Sciences. Morphic is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Morphic$70.81 million39.10-$59.04 million-$1.64-37.54
Myovant Sciences$230.97 million11.36-$205.98 million-$1.91-14.13

Summary

Morphic beats Myovant Sciences on 11 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYOV vs. The Competition

Export to Excel
MetricMyovant SciencesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$2.62B$5.94B$4.53B$14.92B
Dividend YieldN/A2.60%5.94%3.99%
P/E Ratio-14.135.01100.5619.37
Price / Sales11.36334.723,485.059.33
Price / CashN/A18.9691.9623.61
Price / Book-5.354.874.727.36
Net Income-$205.98M$197.65M$117.43M$901.01M

Myovant Sciences Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MORF
Morphic
2.0622 of 5 stars		$56.63
-1.1%		$70.33
+24.2%		+169.9%$2.58B$68.95M-34.53101
INSM
Insmed
1.9336 of 5 stars		$18.69
-0.5%		$43.33
+131.9%		+2.3%$2.55B$245.36M-4.38373
RVNC
Revance Therapeutics
2.1123 of 5 stars		$30.27
-0.6%		$42.36
+40.0%		+135.3%$2.54B$132.57M-6.57495Analyst Report
GLPG
Galapagos
0.8845 of 5 stars		$42.14
-1.7%		$45.37
+7.7%		-24.8%$2.78B$532.48M-15.161,338
SDGR
Schrödinger
2.0612 of 5 stars		$34.47
-4.3%		$50.00
+45.1%		+51.0%$2.46B$197.07M265.17664High Trading Volume
XENE
Xenon Pharmaceuticals
1.8814 of 5 stars		$38.37
-4.3%		$51.50
+34.2%		+33.6%$2.44B$9.43M-16.54149
CORT
Corcept Therapeutics
1.9656 of 5 stars		$23.05
-3.9%		$26.71
+15.9%		+10.0%$2.34B$401.86M28.11238
NUVL
Nuvalent
0.9412 of 5 stars		$40.80
+1.4%		$44.50
+9.1%		+352.8%$2.32BN/A-23.7240Insider Selling
News Coverage
BHC
Bausch Health Companies
2.1536 of 5 stars		$8.19
+0.5%		$8.88
+8.4%		-21.2%$2.96B$8.12B-8.3519,900
SAGE
Sage Therapeutics
1.3032 of 5 stars		$49.60
-1.3%		$51.54
+3.9%		+45.7%$2.96B$7.69M-5.29471

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NYSE:MYOV) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -